Therapy Trends: Rheumatoid Arthritis -- KOL Insight Module
Therapy Trends KOL Insight: Rheumatoid Arthritis analyses the current and predicted key issues, clinical advances and late-stage pipeline products in the international and US RA markets. KOL Insight gives you qualitative, inside information from exclusive FirstWord interviews with 12 key opinion leaders (KOLs) in Europe and the US through the following:
Additionally, Therapy Trends offers you on-going KOL Event Bulletins during the next 12 months. These will cover the latest KOL views on the impact of major RA market events, such as new clinical study results, product approvals and drug withdrawals. FirstWord will deliver these bulletins to you within days of a significant news event.
KOL Insight Benefits
“Rheumatoid arthritis is a crowded market place. Manufacturers see themselves taking over 20 percent of the marketplace, and I think that’s probably unrealistic. I see more of a gradual uptake in three to five years, unless something emerges that’s very unique in the literature.” US Key Opinion Leader
“There are too few trials in very early rheumatoid arthritis or with induction therapy, where you start with the most aggressive therapy and then withdraw medication; I think this will be a trend in the future.” European Key Opinion Leader
“Oral dosing is going to have an advantage for certain group of patients but not as much as you might think. In general, once patients with rheumatoid arthritis learn about the disease and the paradigms of treatment, many recognise that injection or infusion therapy is pretty routine.” US Key Opinion Leader
“The key challenge is finding out how to use the new and existing rheumatoid treatments in the best possible combinations and in the optimal sequence.” European Key Opinion Leader
“With the emergence of these new agents, clinical decision making will be down to physician experience and patient preference.” US Key Opinion Leader
- KOL Insight Report — an in-depth analytical report on RA treatment trends
- Full report updates — issued to you after each major RA market event
- Event Bulletins — the latest KOL views in response to each event
- Assessment of leading Rheumatoid Arthritis market brands
- Analysis of late-stage pipeline therapies
- Predicted market growth in the US and key market regions
- Unmet clinical needs in Rheumatoid Arthritis
- Main factors likely to affect market share of RA drugs in major markets
- The impact of new product entrants and modes of action
- Predicted KOL treatment trends and market leaders
- Ongoing FirstWord RA clinical and market updates
Additionally, Therapy Trends offers you on-going KOL Event Bulletins during the next 12 months. These will cover the latest KOL views on the impact of major RA market events, such as new clinical study results, product approvals and drug withdrawals. FirstWord will deliver these bulletins to you within days of a significant news event.
KOL Insight Benefits
- Recognise the key unmet needs of each disease market
- Identify the challenges facing future disease management
- Learn about specific disease products by class and sub-class
- Review predicted prescribing trends
- Learn about late-stage pipeline products
- Identify current treatment prescribing practices and future treatment algorithms
“Rheumatoid arthritis is a crowded market place. Manufacturers see themselves taking over 20 percent of the marketplace, and I think that’s probably unrealistic. I see more of a gradual uptake in three to five years, unless something emerges that’s very unique in the literature.” US Key Opinion Leader
“There are too few trials in very early rheumatoid arthritis or with induction therapy, where you start with the most aggressive therapy and then withdraw medication; I think this will be a trend in the future.” European Key Opinion Leader
“Oral dosing is going to have an advantage for certain group of patients but not as much as you might think. In general, once patients with rheumatoid arthritis learn about the disease and the paradigms of treatment, many recognise that injection or infusion therapy is pretty routine.” US Key Opinion Leader
“The key challenge is finding out how to use the new and existing rheumatoid treatments in the best possible combinations and in the optimal sequence.” European Key Opinion Leader
“With the emergence of these new agents, clinical decision making will be down to physician experience and patient preference.” US Key Opinion Leader
EXECUTIVE SUMMARY
INTRODUCTION
METHODOLOGY
CURRENT RHEUMATOID ARTHRITIS MARKETPLACE
Current treatment landscape
Rheumatoid Arthritis market definition
Current market overview
Reimbursement of key Rheumatoid Arthritis brands
UK advisory board’s U-turn for wider use of RA drugs
Unmet needs in Rheumatoid Arthritis
Unmet need 1: More efficacious therapies
Unmet need 2: Personalised medicine
Unmet need 3: Earlier diagnosis for treatment
Unmet need 4: Cheaper therapies
Unmet need 5: Improved safety profile
Unmet need 6: Drugs to halt or reverse damage
Unmet need 7: Improved mode of administration
CURRENT RHEUMATOID ARTHRITIS THERAPIES
Pivotal trial data of approved therapies
Anti-TNF therapies
Enbrel (etanercept; Amgen/Pfizer/Takeda) treatment trends
Humira (adalimumab; Abbott/Eisai) treatment trends
Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) treatment trends
Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) treatment trends
Cimzia (certolizumab; UCB) treatment trends
Other biologic therapies
Orencia (abatacept) treatment trends
Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/ Chugai) treatment trends
Actemra/RoActemra (tocilizumab; Chugai/Roche) treatment trends
Current treatment algorithm
Methotrexate: the first-line therapy of choice
Anti-TNFs: second-line RA therapies
The commercial challenge of RA drug switching
Beyond TNF-inhibitors: second and third-line therapies
FUTURE RHEUMATOID ARTHRITIS THERAPIES
Future treatment landscape
Tofacitinib (CP-690,550; Pfizer/Takeda) treatment trends
Fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) treatment trends
Secukinumab (AIN457; Novartis) treatment trends
More aggressive, earlier treatment
Tofacitinib: expanded use as experience rises
Numerous treatment options may confuse prescribers and patients
FUTURE DEVELOPMENTS IN RHEUMATOID ARTHRITIS
Novel targets in the treatment of rheumatoid arthritis
Biosimilar threat is imminent
Eventual development of biomarkers will aid treatment
Patient recruitment will be harder for developers
Clinical trials will have to evolve in the future
FIRSTWORD RHEUMATOID ARTHRITIS NEWS ANALYSIS
Positive Rheumatoid Arthritis key news events
Current therapies
Pipeline therapies
Company therapies
Negative Rheumatoid Arthritis key news events
Marketed therapies
Pipeline therapies
Company therapies
APPENDIX 1
KOL biographies
KOLs from North America
KOLs from Europe
APPENDIX 2
Links to Rheumatoid Arthritis News Stories Jan 2011-May 2012
INTRODUCTION
METHODOLOGY
CURRENT RHEUMATOID ARTHRITIS MARKETPLACE
Current treatment landscape
Rheumatoid Arthritis market definition
Current market overview
Reimbursement of key Rheumatoid Arthritis brands
UK advisory board’s U-turn for wider use of RA drugs
Unmet needs in Rheumatoid Arthritis
Unmet need 1: More efficacious therapies
Unmet need 2: Personalised medicine
Unmet need 3: Earlier diagnosis for treatment
Unmet need 4: Cheaper therapies
Unmet need 5: Improved safety profile
Unmet need 6: Drugs to halt or reverse damage
Unmet need 7: Improved mode of administration
CURRENT RHEUMATOID ARTHRITIS THERAPIES
Pivotal trial data of approved therapies
Anti-TNF therapies
Enbrel (etanercept; Amgen/Pfizer/Takeda) treatment trends
Humira (adalimumab; Abbott/Eisai) treatment trends
Remicade (infliximab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) treatment trends
Simponi (golimumab; Janssen Biotech/Johnson & Johnson/Merck & Co./Mitsubishi Tanabe) treatment trends
Cimzia (certolizumab; UCB) treatment trends
Other biologic therapies
Orencia (abatacept) treatment trends
Rituxan/MabThera (rituximab; Genentech/Biogen Idec/Roche/ Chugai) treatment trends
Actemra/RoActemra (tocilizumab; Chugai/Roche) treatment trends
Current treatment algorithm
Methotrexate: the first-line therapy of choice
Anti-TNFs: second-line RA therapies
The commercial challenge of RA drug switching
Beyond TNF-inhibitors: second and third-line therapies
FUTURE RHEUMATOID ARTHRITIS THERAPIES
Future treatment landscape
Tofacitinib (CP-690,550; Pfizer/Takeda) treatment trends
Fostamatinib disodium (R788; AstraZeneca/Rigel Pharmaceuticals) treatment trends
Secukinumab (AIN457; Novartis) treatment trends
More aggressive, earlier treatment
Tofacitinib: expanded use as experience rises
Numerous treatment options may confuse prescribers and patients
FUTURE DEVELOPMENTS IN RHEUMATOID ARTHRITIS
Novel targets in the treatment of rheumatoid arthritis
Biosimilar threat is imminent
Eventual development of biomarkers will aid treatment
Patient recruitment will be harder for developers
Clinical trials will have to evolve in the future
FIRSTWORD RHEUMATOID ARTHRITIS NEWS ANALYSIS
Positive Rheumatoid Arthritis key news events
Current therapies
Pipeline therapies
Company therapies
Negative Rheumatoid Arthritis key news events
Marketed therapies
Pipeline therapies
Company therapies
APPENDIX 1
KOL biographies
KOLs from North America
KOLs from Europe
APPENDIX 2
Links to Rheumatoid Arthritis News Stories Jan 2011-May 2012
